CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/04/2023
Voltar para busca
Dado oficial do USPTO
BIOSHIN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
49
Atualização mais recente
17/04/2023
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
01/03/2018
Data de registro
22/03/2022
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
22/03/2022
Última transação
22/03/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
19/06/2021
Primeiro uso no comércio
19/06/2021
Código do desenho
4
Tipo de titular
99
Localização do titular
Road Town, Tortola, VG
Examinador
KAJUBI, ELIZABETH
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
BIOHAVEN THERAPEUTICS LTD.
Biohaven Pharmaceutical Holding Company Limited
Representantes
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicated and pharmaceutical preparationsboth prescription and over-the-counterfor use in connection with humans and animalsfor the treatment of central nervous system disordersneurologic illnessespsychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemiapost-stroke recoverysevere intracranial atherosclerosiscarotid endarterectomycardiac bypasscerebral vasculitisreversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuriespost- intracranial hemorrhage recoverytraumatic brain injuryspinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseasesAlzheimer's disease (AD)Amyotrophic Lateral Sclerosis (ALS)Huntington's diseaseLewy body dementiafrontotemporal dementiavascular dementiaParkinson's diseasecognitive impairment of agingprogressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathiesglaucomadiabetic retinopathyischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of painopioid sparing analgesiacancer painchronic neuropathic painperipheral neuropathylow back pain in the nature of failed back surgery syndromeradiculopathy in the nature of sciaticadiabetic peripheral neuropathypost-herpetic neuralgiachemotherapy induced neuropathy and other medication induced neuropathiescomplex regional pain syndromefibromyalgiachronic post-operative paincluster thoracotomyphantom limbstump neuroma; pharmaceutical preparations for the treatment of headache and facial painheadachemigrainechronic daily headachecluster headachetrigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseasesbreath holding in Rett syndromedystoniasdysphagiagait abnormalitiesbulbar function in ALSpseudobulbar affectlevodopa-induced dyskinesias in Parkinson's diseaseagitation in ADdisinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsyprecision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorderstreatment resistant depressionPost Traumatic Stress Disorder (PTSD) in the nature of hyperarousalsubstance abuse disordersaddiction disordersObsessive Compulsive Disorder (OCD)hoardingtrichotillomaniaeating disordersGeneralized Anxiety Disorder (GAD)adjustment disorderspanic disordermajor depressive episodebipolar disorder in the nature of manic and depressive episodesdysthymiacyclothymiapsychotic disordersschizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disordersspinocerebellar ataxiaFriedriech's ataxiamultisystem atrophyessential tremor; pharmaceutical preparations for the treatment of hearing disorderstinnitusdeliriumsleep disordersparasomniaslearning disordersAttention Deficit Disorder (ADD)Pervasive Developmental Disorders (PDD)Asperger's syndromeautismmenopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancermonotherapy and adjunctive use
Publicações
Histórico de despachos e eventos da marca no USPTO.
49 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/04/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/04/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/04/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
17/04/2023
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
11/01/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
22/03/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/02/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/02/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/02/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/02/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/02/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/08/2021
GNRT
NON-FINAL ACTION E-MAILED
04/08/2021
CNRT
SU - NON-FINAL ACTION - WRITTEN
04/08/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
27/06/2021
IUAF
USE AMENDMENT FILED
24/06/2021
EISU
TEAS STATEMENT OF USE RECEIVED
24/06/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
24/12/2020
EX5G
SOU EXTENSION 5 GRANTED
23/12/2020
EXT5
SOU EXTENSION 5 FILED
21/12/2020
EEXT
SOU TEAS EXTENSION RECEIVED
21/12/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/07/2020
EX4G
SOU EXTENSION 4 GRANTED
30/06/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
30/06/2020
EXT4
SOU EXTENSION 4 FILED
17/06/2020
EEXT
SOU TEAS EXTENSION RECEIVED
17/06/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
21/12/2019
EX3G
SOU EXTENSION 3 GRANTED
19/12/2019
EXT3
SOU EXTENSION 3 FILED
19/12/2019
EEXT
SOU TEAS EXTENSION RECEIVED
19/12/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
23/10/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
23/10/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
25/06/2019
EX2G
SOU EXTENSION 2 GRANTED
21/06/2019
EXT2
SOU EXTENSION 2 FILED
21/06/2019
EEXT
SOU TEAS EXTENSION RECEIVED
21/06/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/09/2018
EX1G
SOU EXTENSION 1 GRANTED
10/09/2018
EXT1
SOU EXTENSION 1 FILED
10/09/2018
EEXT
SOU TEAS EXTENSION RECEIVED
10/09/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
26/06/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/05/2018
PUBO
PUBLISHED FOR OPPOSITION
01/05/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/04/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/03/2018
DOCK
ASSIGNED TO EXAMINER
27/03/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/03/2018
NWAP
NEW APPLICATION ENTERED
05/03/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BIOSHIN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.